Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Enterprise value to EBITDA ratio
Latest
-6.48
↓ 106% vs avg
Percentile
P50
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
115.90
Historical baseline
| Period | Value | YoY Change |
|---|---|---|
| 2025 | -6.48 | +27.7% |
| 2024 | -8.97 | -90.4% |
| 2023 | -4.71 | -572.6% |
| 2022 | -0.70 | -143.7% |
| 2021 | 1.60 | +104.4% |
| 2020 | -36.62 | -237.4% |
| 2019 | -10.85 | +51.1% |
| 2018 | -22.21 | -102.0% |
| 2017 | 1132.08 | - |